RAD52 and breast carcinoma: As the two of the identified RAD52 delins carriers were compound heterozygotes for p.Ser346Ter, and one for p.Tyr415Ter (altogether 3/27, 11%), this suggests potential additive effects for the observed RAD52 alterations in breast cancer predisposition.